Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation

被引：20
|
作者：
Delabaudiere, Cyrielle [1 ]
Lavayssiere, Laurence [1 ]
Doerr, Gaelle [1 ]
Muscari, Fabrice [2 ,3 ]
Danjoux, Marie [4 ]
Sallusto, Federico [5 ]
Peron, Jean Marie [3 ,6 ]
Bureau, Christophe [3 ,6 ]
Rostaing, Lionel [1 ,3 ,7 ]
Izopet, Jacques [3 ,7 ,8 ]
Kamar, Nassim [1 ,3 ,7 ]
机构：
[1] CHU Rangueil, Dept Nephrol & Organ Transplantat, F-31059 Toulouse 9, France
[2] Univ Hosp Rangueil, Dept Surg & Liver Transplantat, Toulouse, France
[3] Univ Toulouse 3, F-31062 Toulouse, France
[4] CHU Purpan, Dept Pathol, Toulouse, France
[5] CHU Rangueil, Dept Urol & Kidney Transplantat, F-31059 Toulouse 9, France
[6] CHU Purpan, Dept Hepatol, Federat Digest, Toulouse, France
[7] CHU Purpan, IFR BMT, INSERM, U1043, Toulouse, France
[8] CHU Purpan, Virol Lab, Toulouse, France
来源：
TRANSPLANT INTERNATIONAL | 2015年 / 28卷 / 02期
关键词：
fibrosing cholestatic hepatitis; hepatitis C virus; kidney transplantation; liver transplantation; sofosbuvir; RECIPIENTS; THERAPY; PEGINTERFERON; INFECTION; ALPHA;
D O I：
10.1111/tri.12428
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
Fibrosing cholestatic hepatitis (FCH) is a classical but rare and severe form of recurrent hepatitis C virus (HCV) after liver transplantation. Classical anti-HCV therapy, that is pegylated-interferon (peg-interferon) and ribavirin, has been shown to have limited efficacy in treating FCH. Herein, we report on the first case of successful use of peg-interferon, ribavirin, plus sofosbuvir to treat HCV-induced FCH in a combined liver-kidney transplant patient. Antiviral therapy was given for 24 weeks. HCV clearance occurred within 4 weeks after starting therapy and was maintained until 4 weeks after the end of therapy. Antiviral tolerance was good. We conclude that the use of sofosbuvir-based anti-HCV therapy can be successfully used to treat FCH after a liver or combined kidney-liver transplantation.
引用
收藏
页码：255 / 258
页数：4
相关论文
共 50 条
  • [31] First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder
    Al Nahdi, Nawal
    Ford, Jo-Ann
    Greanya, Erica D.
    Harrigan, Jo-Ann
    Tse, Irene
    Steinbrecher, Urs P.
    Erb, Siegfried R.
    Yoshida, Eric M.
    ANNALS OF HEPATOLOGY, 2013, 12 (01) : 156 - 160
  • [32] Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program
    Litwin, Alain H.
    Harris, Kenneth A., Jr.
    Nahvi, Shadi
    Zamor, Philippe J.
    Soloway, Irene J.
    Tenore, Peter L.
    Kaswan, Daniel
    Gourevitch, Marc N.
    Arnsten, Julia H.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2009, 37 (01) : 32 - 40
  • [33] Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy
    Cure, Sandrine
    Guerra, Ines
    Camma, Calogero
    Craxi, Antonio
    Carosi, Giampiero
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (09) : 678 - 690
  • [34] Preemptive therapy with pegylated interferon alpha-2b and ribavirin after liver transplantation for hepatitis C cirrhosis
    Castedal, M
    Felldin, M
    Bäckman, L
    Olausson, M
    Friman, S
    TRANSPLANTATION PROCEEDINGS, 2005, 37 (08) : 3313 - 3314
  • [35] Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients
    Abdel-Moneim, Adel
    Abood, Alaa
    Abdel-Gabaar, Mohamed
    Zanaty, Mohamed I.
    Ramadan, Mohamed
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2018, 4 (03) : 191 - 196
  • [36] Factors associated with efficacy of pegylated interferon-α plus ribavirin for chronic hepatitis C after renal transplantation
    Li, Ling-Fei
    Shi, Ke-Qing
    Lin, Yi-Qian
    Wang, Li-Ren
    He, Jiang-Ping
    Braddock, Martin
    Chen, Yong-Ping
    Zheng, Ming-Hua
    GENE, 2014, 544 (02) : 101 - 106
  • [37] Effectiveness and safety of sofosbuvir-based therapy against chronic hepatitis C infection after successful kidney transplantation
    Musialik, Joanna
    Kolonko, Aureliusz
    Kwiecien, Katarzyna
    Owczarek, Aleksander J.
    Wiecek, Andrzej
    TRANSPLANT INFECTIOUS DISEASE, 2019, 21 (03)
  • [38] Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation
    Ciesek, S.
    Proske, V.
    Otto, B.
    Pischke, S.
    Costa, R.
    Luethgehetmann, M.
    Polywka, S.
    Klempnauer, J.
    Nashan, B.
    Manns, M. P.
    von Hahn, T.
    Lohse, A. W.
    Wedemeyer, H.
    Mix, H.
    Sterneck, M.
    TRANSPLANT INFECTIOUS DISEASE, 2016, 18 (03) : 326 - 332
  • [39] Successful Antiviral and Antituberculosis Treatment With Pegylated Interferon-alfa and Ribavirin in a Chronic Hepatitis C Patient With Pulmonary Tuberculosis
    Tsai, Ming-Chao
    Lin, Meng-Chih
    Hung, Chao-Hung
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2009, 108 (09) : 746 - 750
  • [40] Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation
    Mariarosa Tamè
    Federica Buonfiglioli
    Massimo Del Gaudio
    Andrea Lisotti
    Paolo Cecinato
    Antonio Colecchia
    Francesco Azzaroli
    Antonietta D’Errico
    Rosario Arena
    Claudio Calvanese
    Chiara Quarneti
    Giorgio Ballardini
    Antonio Daniele Pinna
    Giuseppe Mazzella
    World Journal of Gastroenterology, 2013, (32) : 5278 - 5285
12345